explore -WSS

explore

author：explore 2025-09-07 06:38:16 - browse：36212

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Eli Lilly CEO gives to Mike Pence presidential super PAC

WSS

Biogen’s boardroom scandal saddles CEO with first crisis

Why the drug industry's warnings on the IRA's impact fall short

People with substance use disorder deserve online privacy

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Bird flu researchers hone in on Finland’s mink farms

Neurocrine congenital adrenal hyperplasia trial succeeds

hotspot

explore

knowledge

At least 13 dead in Texas as scorching temps continue

Hospitals are dialing back on venture capital investing

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Trump demands the U.S. pay no more for drugs than other countries … again

David Liu startup to focus on CRISPR delivery

Activists slam private health insurers over coverage restrictions

Judge sides with young activists in first

How to save PrEP access — and even expand it

Indictment alleges Trump's ex

hotspot

After Optum profits sink, UnitedHealth makes changes

Senate bill would ban some hospital facility fees

Senate bill would ban some hospital facility fees

Megan Rapinoe shares emotional post following US Women's World Cup exit

Treatments for cramps don't cut it. Why aren't there better options?

Why the quest to eradicate polio has stumbled

focus

focus

entertainment

hotspot